Last reviewed · How we verify
stop oral angiogenesis inhibitor
stop oral angiogenesis inhibitor is a Small molecule drug developed by Radboud University Medical Center. It is currently FDA-approved.
At a glance
| Generic name | stop oral angiogenesis inhibitor |
|---|---|
| Sponsor | Radboud University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (PHASE4)
- Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer (PHASE3)
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma (PHASE1, PHASE2)
- Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer (PHASE2)
- Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors (PHASE2)
- Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- stop oral angiogenesis inhibitor CI brief — competitive landscape report
- stop oral angiogenesis inhibitor updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI
Frequently asked questions about stop oral angiogenesis inhibitor
What is stop oral angiogenesis inhibitor?
stop oral angiogenesis inhibitor is a Small molecule drug developed by Radboud University Medical Center.
Who makes stop oral angiogenesis inhibitor?
stop oral angiogenesis inhibitor is developed and marketed by Radboud University Medical Center (see full Radboud University Medical Center pipeline at /company/radboud-university-medical-center).
What development phase is stop oral angiogenesis inhibitor in?
stop oral angiogenesis inhibitor is FDA-approved (marketed).